Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of cancer. Founded in 2006 and headquartered in Waltham, Massachusetts, the company’s research centers on epigenetic modulation and immune-oncology approaches to address unmet needs in oncology. Syndax is advancing a pipeline designed to enhance the efficacy of existing cancer treatments and to overcome therapy resistance.
The company’s lead product candidate is entinostat, a selective class I histone deacetylase (HDAC) inhibitor. Entinostat is being evaluated in a pivotal Phase 3 trial, known as E2112, for estrogen receptor–positive metastatic breast cancer in combination with the aromatase inhibitor exemestane. Beyond breast cancer, Syndax has granted rights to Taiho Oncology for the development and commercialization of entinostat in certain Asian territories, including gastric and other solid tumor indications.
In addition to its late-stage program, Syndax is exploring combination therapies that pair entinostat with immune checkpoint inhibitors in various solid tumors. The company’s preclinical and early clinical studies aim to leverage HDAC inhibition to prime the tumor microenvironment and enhance anti-tumor immune responses. This dual-modality strategy underscores Syndax’s commitment to creating synergistic regimens that may improve outcomes in cancers that are refractory to standard treatments.
Operating primarily in North America, Syndax also collaborates with international partners to conduct global clinical trials and to extend its geographic reach. The company’s leadership team comprises seasoned executives with extensive experience in oncology drug development, regulatory strategy and commercialization. Through strategic alliances and a focused research agenda, Syndax Pharmaceuticals continues to advance its mission of delivering transformative therapies to patients with cancer.
AI Generated. May Contain Errors.
Free SNDX Stock Alerts